TY - JOUR
T1 - Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients
AU - Yao, Nai Shun
AU - Wu, Yi Ying
AU - Janckila, Anthony J.
AU - Ku, Chih Hung
AU - Hsieh, An Tai
AU - Ho, Ching Liang
AU - Lee, Su Huei
AU - Chao, Tsu Yi
N1 - Funding Information:
This study was supported by a grant issued from the National Science Council of Taiwan ( NSC 95-2314-B-016-006 ). The authors would like to thank In-Sang Deng and Hsin-Yi Liu for their assistance in data collection.
PY - 2011/1/14
Y1 - 2011/1/14
N2 - Background: Diagnosis and follow-up of bone metastasis (BMet) in non-small cell lung cancer (NSCLC) patients usually rely on symptoms and image studies. A serum marker of bone resorption may improve the quality of treatment in such patients. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a specific marker for osteoclasts and we proposed it can be used as a marker of BMet in NSCLC patients. Methods: In November 2002 till August 2008 serum samples were obtained from 141 newly diagnosed stage IIIA, IIIB or IV NSCLC patients and 41 normal subjects. All patients received baseline bone scintinography examination and evaluation of clinical symptoms as a standard of BMet diagnosis. Patients were divided into 2 groups by having BMet (Group I, n= 72) or not (Group II, n= 69). An in-house immunoassay using a TRACP-specific monoclonal antibody, 14G6, was used to measure the serum TRACP5b activity at pH 6.1. Results: The mean serum TRACP5b activities of Group I, Group II and normal subjects were 3.50. ±. 2.23. U/l, 2.09. ±. 0.72. U/l and 2.33. ±. 0.52. U/l, respectively. After adjusting for age, stage, gender, and histology in a generalized linear model, Group I has significantly higher TRACP5b activity than Group II (p
AB - Background: Diagnosis and follow-up of bone metastasis (BMet) in non-small cell lung cancer (NSCLC) patients usually rely on symptoms and image studies. A serum marker of bone resorption may improve the quality of treatment in such patients. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a specific marker for osteoclasts and we proposed it can be used as a marker of BMet in NSCLC patients. Methods: In November 2002 till August 2008 serum samples were obtained from 141 newly diagnosed stage IIIA, IIIB or IV NSCLC patients and 41 normal subjects. All patients received baseline bone scintinography examination and evaluation of clinical symptoms as a standard of BMet diagnosis. Patients were divided into 2 groups by having BMet (Group I, n= 72) or not (Group II, n= 69). An in-house immunoassay using a TRACP-specific monoclonal antibody, 14G6, was used to measure the serum TRACP5b activity at pH 6.1. Results: The mean serum TRACP5b activities of Group I, Group II and normal subjects were 3.50. ±. 2.23. U/l, 2.09. ±. 0.72. U/l and 2.33. ±. 0.52. U/l, respectively. After adjusting for age, stage, gender, and histology in a generalized linear model, Group I has significantly higher TRACP5b activity than Group II (p
KW - Bone metastasis
KW - Lung cancer
KW - Osteoclast
KW - Tartrate-resistant acid phosphatase 5b
UR - http://www.scopus.com/inward/record.url?scp=78650512206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650512206&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2010.09.038
DO - 10.1016/j.cca.2010.09.038
M3 - Article
C2 - 20932965
AN - SCOPUS:78650512206
SN - 0009-8981
VL - 412
SP - 181
EP - 185
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 1-2
ER -
